Pomerantz LLP is investigating Agios Pharmaceuticals and some of its executives for possible securities fraud following the company's announcement that its Phase 2 trial for tebapivat in sickle cell disease patients failed to meet expectations. The trial results led Agios to halt development of the drug, causing the stock to drop 6.74% on July 21, 2026. The investigation aims to determine if the company misled investors or engaged in unlawful practices. Investors affected are encouraged to contact the law firm for potential class action participation.
Ethereum's euro-denominated stablecoin market cap grew by $32 million in the past 30 days, making up most of a $39.9 million increase across three networks. This growth highlights Ethereum's dominance with a 69.5% market share in a sector that expand...
The Amplify CEF High Income ETF (YYY) invests in 60 closed-end funds (CEFs) chosen for yield, discount, and liquidity, providing a strong 13.3% distribution yield. However, the fund has shown significant and consistent underperformance compared to it...
This week, 10 notable stocks including McDonald's (MCD), Microsoft (MSFT), JPMorgan Chase (JPM), and Ingredion (INGR) announced dividend increases. Microsoft stands out for its high quality rating, low payout ratio, and dividend safety, though its yi...
Best Buy reported strong quarterly earnings, but ongoing economic issues like poor consumer sentiment, high inflation, and energy costs raise concerns. The analyst believes the current stock price is overvalued and does not justify holding the stock....
LG Display has introduced the world's first 24.5-inch 720Hz Gaming OLED panel designed specifically for esports monitors. This panel offers the highest refresh rate of 720Hz and an ultra-fast response time of 0.02ms, significantly reducing motion blu...
